Marshall Wace, LLP Standard Biotools Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Standard Biotools Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 58,145 shares of LAB stock, worth $129,663. This represents 0.0% of its overall portfolio holdings.
Number of Shares
58,145
Previous 81,617
28.76%
Holding current value
$129,663
Previous $144,000
22.22%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding LAB
# of Institutions
143Shares Held
279MCall Options Held
27.2KPut Options Held
34.1K-
Casdin Capital, LLC New York, NY71.3MShares$159 Million10.68% of portfolio
-
Viking Global Investors LP58.7MShares$131 Million0.44% of portfolio
-
Black Rock Inc. New York, NY21.8MShares$48.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA17.3MShares$38.6 Million0.0% of portfolio
-
Morgan Stanley New York, NY15.2MShares$34 Million0.0% of portfolio
About STANDARD BIOTOOLS INC.
- Ticker LAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 78,654,800
- Market Cap $175M
- Description
- Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar ...